Altered fibrin-clot properties are associated with retinopathy in type 2 diabetes mellitus

Diabetes and Metabolism

Volumn 38, Issue 5, 2012, Pages 462-465

  Walus Miarka, M ^a   Wolkow, P ^a   Cyganek, K ^b   Mirkiewicz Sieradzka, B ^b   Malecki, M T ^a,b   Undas, A ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

Coagulation; Complications; Fibrin clot; Retinopathy

Indexed keywords

FIBRIN; GLUCOSE; INSULIN;

ADULT; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE DURATION; EYE EXAMINATION; FEMALE; FIBRIN CLOT; FIBRINOLYSIS; GENDER; GLUCOSE TOLERANCE TEST; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS;

BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; FEMALE; FIBRIN; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84869099983     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2012.03.007     Document Type: Article

References (16)

1. Frank R.N. Diabetic retinopathy. N Engl J Med 2004, 350:48-58.
2. Malecki M.T., Cyganek K., Mirkiewicz-Sieradzka B., Wolkow P.P., Wanic K., Skupien J., et al. Alanine variant of the Pro12Ala polymorphism of the PPARgamma gene might be associated with decreased risk of diabetic retinopathy in type 2 diabetes. Diabet Res Clin Pract 2008, 80:139-145.
3. Grant P.J. Inflammatory, atherothrombotic aspects of type 2 diabetes. Curr Med Res Opin Suppl 2005, 1:S5-S12.
4. Hess K., Grant P.J. Inflammation and thrombosis in diabetes. Thromb Haemost 2011, 105(Suppl. 1):S43-S54.
5. Juhan-Vague I., Roul C., Alessi M., Ardissone J., Heim M., Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulin. Thromb Haemost 1989, 61:370-373.
6. Boden G., Vaidyula V.R., Homko C., Cheung P., Rao A.K. Circulating tissue factor procoagulant activity and thrombin generation in patients with type 2 diabetes: effects of insulin and glucose. J Clin Endocrinol Metab 2007, 92:4352-4358.
7. Heywood D.M., Mansfield M.W., Grant P.J. Factor VII gene polymorphisms, factor VII: C levels and features of insulin resistance in non-insulin-dependent diabetes mellitus. Thromb Haemost 1996, 75:401-406.
8. Alzahrani S.H., Ajjan R.A. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 2010, 7:260-273.
9. Pieters M., van Zyl D.G., Rheeder P., Jerling J.C., Loots du T., van der Westhuizen F.H., et al. Glycation of fibrinogen in uncontrolled diabetic patients and the effects of glycaemic control on fibrinogen glycation. Thromb Res 2007, 120:439-446.
10. Jörneskog G., Egberg N., Fagrell B., Fatah K., Hessel B., Johnsson H., et al. Altered properties of fibrin gel structure in patients with IDDM. Diabetologia 1996, 39:1519-1523.
11. Dunn E.J., Philippou H., Ariëns R.A., Grant P.J. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006, 49:1071-1080.
12. Dunn E.J., Ariëns R.A., Grant P.J. The influence of type 2 diabetes on clot structure and function. Diabetologia 2005, 48:1198-1206.
13. Standeven K.F., Ariëns R.A., Whitaker P., Ashcroft A.E., Weisel J.W., Grant P.J. The effect of dimethylbiguanide on thrombin activity. FXIII activation, fibrin polymerization, and fibrin clot formation. Diabetes 2002, 51:189-197.
14. Undas A., Zawilska K., Ciesla-Dul M., Lehmann-Kopydlowska A., Skubiszak A., Ciepluch K., et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009, 114:4272-4278.
15. Undas A., Celinska-Löwenhoff M., Löwenhoff T., Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006, 4:1029-1036.
16. Charm S.E., Wong B.L. Shear degradation of fibrinogen in the circulation. Science 1970, 23(170):466-468.